The city of Pensacola, Florida, currently has 5 active clinical trials seeking participants for Multiple Sclerosis research studies.
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/22/2025
Locations: Panhandle Research and Medical Clinic, Pensacola, Florida
Conditions: Multiple Sclerosis
Register for Updates
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/14/2025
Locations: Emerald Coast Neurology, Pensacola, Florida
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/14/2025
Locations: Emerald Coast Neurology, Pensacola, Florida
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343
Recruiting
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Emerald Coast Neurology/Synergy Clinical Research, Pensacola, Florida
Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Pensacola, Florida
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates